Journal
PHARMACEUTICS
Volume 12, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics12070624
Keywords
infectious diseases; 3-indole carboxaldehyde; microbiota; host-microbiota-pathogen interface; antimicrobial resistance; postbiotics; tryptophan metabolites
Categories
Funding
- Italian Cystic Fibrosis Research Foundation [24/2018]
Ask authors/readers for more resources
Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available